Cargando…
DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer
SIMPLE SUMMARY: Non-small-cell lung carcinoma (NSCLC) covers for almost 85% of all lung cancers and a major contributor to the overall cancer death rate. Erlotinib is used to treat NSCLC via inhibition of epithelial growth factor receptor (EGFR) kinase activity. Despite its high efficacy, recurrence...
Autores principales: | Kim, Tae Young, Ji, Eun Sun, Lee, Ju Yeon, Kim, Jin Young, Yoo, Jong Shin, Szasz, A. Marcell, Dome, Balazs, Marko-Varga, Gyorgy, Kwon, Ho Jeong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564424/ https://www.ncbi.nlm.nih.gov/pubmed/32933200 http://dx.doi.org/10.3390/cancers12092613 |
Ejemplares similares
-
Matrix‐assisted laser desorption ionization ‐ mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a non‐small‐cell lung cancer mouse xenograft model
por: Kim, Tae Young, et al.
Publicado: (2021) -
Proteomic analysis enables distinction of early‐ versus advanced‐stage lung adenocarcinomas
por: Kelemen, Olga, et al.
Publicado: (2020) -
Biobank integration of large-scale clinical and histopathology melanoma studies within the European Cancer Moonshot Lund Center
por: Malm, Johan, et al.
Publicado: (2018) -
Differential expression and methylation of integrin subunit alpha 11 and thrombospondin in the amnion of preterm birth
por: Yoo, Jae Young, et al.
Publicado: (2018) -
Challenging the heterogeneity of disease presentation in malignant melanoma—impact on patient treatment
por: Marcell Szasz, A., et al.
Publicado: (2018)